UCB S.A.

The UK’s originator drugs and generics industries are at odds over a rise in the clawbacks that companies must pay the government on the sales of branded medicines to the National Health Service under

Roivant subsidiary Immunovant announced positive Phase III data for its neonatal fragment crystallizable receptor (FcRn) inhibitor batoclimab in myasthenia gravis (MG), but a key piece of the update i

Planning for top-seller Jakafi’s (ruxolitinib) US patent expiration in 2028, Incyte reported positive top-line data from a pair of Phase III trials of selective JAK1 inhibitor povorcitinib in hidraden

Praxis Precision Medicines is not giving up on ulixacaltamide in essential tremor (ET) after the independent data monitoring committee (IDMC) for the Phase III Essential3 program said one of the progr